“Our results suggest that in patients with a contraindication to immunotherapy, such as connective tissue, rheumatologic, or interstitial lung disease, bevacizumab may be a reasonable alternative, instead of pembrolizumab, to add to carboplatin-pemetrexed,” said lead author, Stephen J. Bagley, MD, MSCE, assistant professor of hematology-oncology at Abramson Cancer Center, in a statement.
Patients with advanced nonsquamous non—small cell lung cancer (NSCLC) have been shown to benefit from the addition of the immune checkpoint inhibitor pembrolizumab to first-line carboplatin and pemetrexed regardless of programmed death ligand-1 (PD-L1) expression. However, some patients cannot receive PD-1 inhibitors because of comorbidities, or because they lack access. In such cases, says a new study, bevacizumab (Avastin, which has 1 FDA-approved biosimilar, Mvasi) may be an option.
The study, conducted by researchers at the Abramson Cancer Center at the University of Pennsylvania, used deidentified electronic health record data, representing more than 260 cancer clinics, from Flatiron Health’s database. The investigators assessed a cohort of 4724 patients with advanced NSCLC.
In total, 2759 patients received carboplatin and pemetrexed, and 1965 received carboplatin and pemetrexed plus bevacizumab. The investigators found that median overall survival (OS) was 12.1 months (95% CI, 11.2-12.9) in the carboplatin and pemetrexed plus bevacizumab group versus with 8.6 months (95% CI, 8.1-9.1) in the carboplatin and pemetrexed group (P <.001). Bevacizumab was also associated with improved OS in a multivariate model (hazard ratio, 0.80; 95% CI, 0.75-0.86; P <.001).
In a cohort of patients who were treated at the University of Pennsylvania, data collected via manual chart abstraction allowed for a secondary analysis that showed that the survival benefit was maintained after adjusting for potential confounders of the relationship between bevacizumab use and survival, including brain metastases, anticoagulation use, and recent history of hemoptysis. Bevacizumab also proved to be beneficial in subgroups limited to patients who were elderly.
“Our results suggest that in patients with a contraindication to immunotherapy, such as connective tissue, rheumatologic, or interstitial lung disease, bevacizumab may be a reasonable alternative, instead of pembrolizumab, to add to carboplatin-pemetrexed,” said lead author, Stephen J. Bagley, MD, MSCE, assistant professor of hematology-oncology at Abramson Cancer Center, in a statement.
“Many oncologists were already using carboplatin-pemetrexed-bevacizumab for patients with advanced non-squamous NSCLC, but this study suggests there is indeed an improvement in overall survival when bevacizumab is added. What’s more, I was surprised to learn that the survival benefit of bevacizumab persisted even in older patients and after adjusting for brain metastases, hemoptysis, and anticoagulation use,” Bagley added.
Bagley and his coauthors write that these real-world results can help in the complex clinical decision-making necessary for patients with NSCLC.
Reference
Bagley SJ, Talento S, Mitra N, et al. Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous non—small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5). doi: 10.6004/jnccn.2018.7102.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.